|
WO2016118670A1
|
|
Multigene expression assay for patient stratification in resected colorectal liver metastases
|
|
WO2016106326A1
|
|
Polymorph of granaticin b
|
|
WO2016100901A1
|
|
Urinary catheter for facilitating control of bladder content volume and methods for use thereof
|
|
CN107206077A
|
|
Target the antibody and application method of G G-protein linked receptors
|
|
WO2016081732A1
|
|
Thienopyrimidines and uses thereof
|
|
WO2016065044A1
|
|
Methods for drug discovery
|
|
WO2016061073A1
|
|
Composition and method for in vivo engineering of chromosomal rearrangements
|
|
WO2016049280A1
|
|
mTORC1 MODULATION
|
|
WO2016044790A1
|
|
Methods for treating brain metastasis
|
|
CN106715469A
|
|
Antibodies, compositions, and uses
|
|
WO2016028749A1
|
|
Raman-triggered ablation/resection systems and methods
|
|
US2016067362A1
|
|
Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
|
|
CN107074949A
|
|
Anti- ceramide antibody
|
|
US2016095920A1
|
|
Kras mutations and resistance to anti-egfr treatment
|
|
US2015343100A1
|
|
Bimodal fluorophore-labeled liposomes and associated methods and systems
|
|
US2015342960A1
|
|
Drug combinations for treatment of melanoma and other cancers
|
|
WO2015176056A1
|
|
One-step labeling of antibodies to high specific activity with actinium-225
|
|
WO2015172085A2
|
|
Biomarkers for response to pi3k inhibitors
|
|
US2016131651A1
|
|
Gamma-Secretase Substrates and Methods of Use
|
|
WO2015161192A1
|
|
Fucoidan nanogels and methods of their use and manufacture
|
